Compare MI & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MI | ACRV |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.3M | 47.6M |
| IPO Year | 2022 | 2022 |
| Metric | MI | ACRV |
|---|---|---|
| Price | $5.39 | $1.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 12.9K | ★ 812.7K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $805.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $1.05 |
| 52 Week High | $6.70 | $5.75 |
| Indicator | MI | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 61.63 | 41.45 |
| Support Level | $3.65 | $1.51 |
| Resistance Level | $6.70 | $2.47 |
| Average True Range (ATR) | 0.74 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 51.30 | 22.47 |
NFT Ltd operates an online electronic platform for offering and trading artwork. Through its platform, the company allows artists/art dealers/owners to access a much bigger art trading market where artists can engage with a wide range of investors. Its platform also invests in high-end artwork accessible to ordinary people without financial resources. The company's trading platforms comprise the sale of calligraphies and paintings, jewelry, and precious stones. It generates revenue in the form of services in connection with the offering and trading of artwork on its system, consisting of listing fees, trading commissions, and management fees.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.